Ivermectin taken at the start of pregnancy is not associated with an increased risk of adverse pregnancy outcomes
A study conducted by the Barcelona Institute for Global Health found no increased risk of adverse pregnancy outcomes for women inadvertently exposed to ivermectin during early pregnancy. While the findings suggest safety, researchers note the sample size is too small to change current medical recommendations.
Why it matters
Ivermectin is widely used for tropical disease control, and clarifying its safety profile during pregnancy is critical for public health policy in endemic regions.
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Pixabay/CC0 Public Domain A study led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by the "la Caixa" Foundation, found no increased risk of miscarriage, stillbirth or major congenital anomalies among women inadvertently exposed to ivermectin from two weeks before conception through the first four weeks of pregnancy. The findings, published in eClinicalMedicine , add to the available evidence on the safety of this antiparasitic drug during the very early stages of pregnancy, although the researchers stress that the number of cases remains too small to warrant changes to current recommendations.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in